The Seoul Central District Court ruled against Regeneron, which had sought to block Samsung Bioepis from producing and selling a biosimilar referencing the US firm’s Eylea, a blockbuster medicine used ...

For crafting engaging magazines, posters, flyers, brochures, and other essential print and electronic publications, the best DTP software is an essential tool. And after comprehensive testing ...

The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL ...

We are now preparing for the launch of bBevacizumab, branded Jobevne, and have secured an entry date in the second half of 2026 for Yesafili (bAflibercept), a biosimilar to Eylea. We have also ...

Bayer earns license revenues from JNJ for Xarelto sales in the United States. Sales of the ophthalmology drug, Eylea, increased 4.7% to €815 million, driven by higher volumes. The launch of ...

Collette has released a new brochure dedicated to the curated tours in one of its top regions – Italy. To celebrate the launch, Collette is encouraging travellers to take advantage of its ...

CEO Leonard Schleifer specifically cited a funding gap at patient assistance foundations as a catalyst for more patients and physicians turning to off-label Avastin over EYLEA, resulting in a ...

Additionally, sales for opthalmology drug Eylea, which Bayer has ex-US rights, may face declines as biosimilar competition for the low-dose version offset growth from the recently launched high ...

Drug Name Manufacturer(s) Total Spending Primary Use Keytruda Merck & Co. MRK $4.0B Cancer (various types) Eylea Regeneron Pharmaceuticals Inc. REGN $3.4B Macular degeneration Prolia/Xgeva Amgen ...

In Japan, this would be the third indication for aflibercept 8 mg supporting the blockbuster status of Eylea. The submission to the MHLW is supported by favorable outcomes from the global randomized, ...

A brochure shared on Reddit provides new details on Eufy’s first smart display. According to the brochure, the Smart Display E10 features an eight-inch touchscreen with an HD resolution.

The settlement terms remain confidential. Yesafili was approved by the FDA in May 2024 as an interchangeable biosimilar, meaning it can be substituted for Eylea at the pharmacy without prescriber ...